Preoperative Levels of Matrix Metalloproteinase-7 and -9 and Tissue Inhibitor of Matrix Metalloproteinase-1 Relation to Pathologic Parameters in Bladder Carcinoma Patients |
Gunes, Mustafa
(Department of Urology, Yuzuncu Yil University Medical Faculty)
Kemik, Ahu Serap (Department of Biochemistry, Cerrahpasa Medical Faculty, University of Istanbul) Pirincci, Necip (Department of Urology, Yuzuncu Yil University Medical Faculty) Gecit, Ilhan (Department of Urology, Yuzuncu Yil University Medical Faculty) Taken, Kerem (Urology Clinic of Van State Hospital) Yuksel, Mehmet Bilgehan (Department of Urology, Celal Bayar University Medical Faculty) Kaba, Mehmet (Urology Clinic of Van State Hospital) Eryilmaz, Recep (Department of Urology, Yuzuncu Yil University Medical Faculty) |
1 | Anton-Culver H, Lee-Feldstein A, Taylor TH (1992). Occupation and bladder cancer risk. Am J Epidemiol, 136, 89-94. |
2 | Andersen JB, Aaboe M, Borden EC, et al (2006). Stage-associated overexpression of the ubiquitin-like protein, ISG15, in bladder cancer. Br J Cancer, 94, 1465-71. DOI ScienceOn |
3 | Cheng HC, Yang HB, Chang WL, et al (2012). Expressions of MMPs and TIMP-1 in gastric ulcers may differentiate H. pylori-infected from NSAID-related ulcers. Sci World J, 10, 539316. |
4 | Cornelius LA, Nehring LC, Harding E, et al (1998). Matrix metalloporteinases generate angiostatin: effect of neovascularization. J Immunol, 161, 6845-52. |
5 | Durkan GC, Nutt JE, Marsh C, et al (2003). Alteration in urinary matrix metalloproteinase-9 to tissue inhibitor of metalloproteinase-1 ratio predicts recurrence in nonmuscle-invasive bladder cancer. Clin Cancer Res, 9, 2576-82. |
6 | Egeblad M, Werb Z (2009). New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer, 2, 161-74. |
7 | Guan KP, Hou SK, Yan Z, Ye HY (2003). Serum levels of endostatin and MMP-9 associated with high-stage and grade primary transitional cell carcinoma of the bladder cancer. Urology, 61, 719-23. DOI ScienceOn |
8 | Hashimoto K, Kihira Y, Matuo Y, Usui T (1998). Expression MMP-7 and TIMP-1 in human prostate. J Urol, 160, 1872-6. DOI ScienceOn |
9 | Hurst NG, Stocken DD, Wilson S, et al (2007). Elevated serum MMP-9 concentration predicts the presence of colorectal neoplasia in symptomatic patients. Br J Cancer, 97, 971-77. DOI ScienceOn |
10 | Hayakawa T, Yamashita K, Tanzawa K, et al (1992). Growth-promoting activity of tissue inhibitor of matrix metalloproteinase-1 for a wide range a cells. A possible new growth factor in serum. FEBS Lett. 298, 29-32. DOI ScienceOn |
11 | Johansen JL, Cohen SM (1997) Epidemiology and etiology of bladder cancer. Semin Surg Oncol, 13, 291-8. DOI ScienceOn |
12 | Kanayama H (2001) Matrix metalloproteinases and bladder cancer. J Med Invest, 48, 31-43. |
13 | Lipton A, Ali S, Demers L, et al (2007). Elevated plasma tissue inhibitor of metalloproteinase-1 level predicts decreased response and survival in metastatic breast cancer. Cancer 109, 1933-8. DOI ScienceOn |
14 | Koss LG, Deitch D, Ramathan R, Sherman AB (1985) Diagnostic value of cytology of voided urine. Acta Cytol, 29, 810-6. |
15 | Laleur MA, Handsley MM, Knauper V, Murphy G, Edwards DR (2002). Endothelial tubulogenesis within fibrin gels specifically requires the activity of membrane-type-matrix metalloproteinases. J Cell Sci, 115, 3427-8. |
16 | Leelawat K, Narong S, Wannaprasert J, Ratanashu T (2010). Prospective study of MMP-7 levels in the cholangiocarcainoma. World J Gastro, 16, 4697-703. DOI |
17 | Li G, Fridman R, Kim HR (1999). TIMP-1 inhibits apopotosis of human breast epithelial cells. Cancer Res, 59, 6267-75. |
18 | Martinez-Fernandez A, Garcia-Albeniz X, Pineda E, et al (2009). Serum matrilysin levels predict outcome curatively resected colorectal cancer patients. Ann Surg Oncol, 16, 1412-20. DOI |
19 | McQuibban GA, Gong JH, Wong JB, et al (2000). Inflammation dampened by gelatinase A cleavage of monocyte chemoattractant protein-3. Science, 289, 1202-06. DOI ScienceOn |
20 | McQuibban GA, Butler GS, Gong JH, et al (2001). Matrix metalloproteinase activity inactivates the CXC chemokine stromal cell-derived factor-1. J Biol Chem, 276, 43503-8. DOI ScienceOn |
21 | Murray D, Morrin M, Mc Donnel S (2004) Increased invasion and expression of MMP-9 in human colorectal lines by a CD44-dependent mechanism. Anticancer Res, 24, 489-94. |
22 | Naruo S, Kanayama H, Takigawa H (1994) Serum levels of TIMP-1 in bladder cancer patients. Int J Urol, 1, 228-31 DOI ScienceOn |
23 | Sheu BC, Hsu SM, Ho HN, et al (2001). A novel role of metalloproteinase in cancer-mediated immunosuppression. Cancer Res, 61, 237-42. |
24 | Park HD, Kang ES, Kim JW, et al (2012). Serum CA19-9, cathepsin D, and matrix metalloproteinase-7 as a diagnostic panel for pancreatic ductal adenocarcinoma. Proteomics, 12, 3590-7. DOI ScienceOn |
25 | Ray JM, Stetler-Stevenson WG (1994) The role of matrix metalloproteinase and their inhibitors in tumor invasion, metastasis and angiogenesis. Eur Respir J, 7, 2062-72. |
26 | Sharma S, Ksheersagar P, Sharma P (2009) Diagnosis and treatment of bladder cancer. Am Family Physician, 80, 717-23. |
27 | Slaton JW, Millikan R, Inoue K, et al (2004). Correlation of metastasis related gene expression and relapse-free survival in patients with locally advanced bladder cancer treated cystectomy and chemotherapy. J Urol, 171, 570-4. DOI ScienceOn |
28 | Szarvas T, Jager T, Becker M, et al (2011). Validation of circulating MMP-7 level as an independent prognostic marker of poor survival in urinary bladder cancer. Pathol Oncol Res, 17, 325-32. DOI ScienceOn |
29 | Szarvas T, Becker M, vom Dorp F, et al (2010). MMP-7 as a marker of metastasis and predictor of poor urvival in bladder cancer. Cancer Sci, 101, 1300-8.l DOI ScienceOn |
30 | Szarvas T, Singer BB, Becker M, et al (2010). Urinary MMP-7 level is associated with the presence of metastasis in bladder cancer. BJU Int, 7, 1069-73. |
31 | Torii A, Kodera Y, Uesaka K, et al (1997). Plasma concentration of MMP-9 in gastric cancer. Br J Cancer, 84, 133-6. |
32 | Wallard MJ, Pennington CJ, Veerakumarasivam A, et al (2006). Comprehensive profiling and localization of the matrix metalloproteinases in urothelial carcinoma. Br J Cancer, 94, 569-77. DOI ScienceOn |
33 | Yang B, Su K, Gao J, Rao Z (2012) Expression and prognostic value of matrix metalloproteinase-7 in colorectal cancer. Asian Pac J Cancer Prev, 13, 1049-52. DOI ScienceOn |
34 | Wu ZS, Wu Q, Yang JH, et al (2008). Prognostic significance of MMP-9 and TIMP-1 serum and tissue expression in breast cancer. Int J Cancer, 122, 2050-6. DOI ScienceOn |
35 | Vargo-Gogola T, Crawford HC, Fingleton B, Matrisian LM (2002). Identification of novel matrix metalloproteinase-7 cleavage sites in murine and human Fas ligand. Arch Biochem Biophys, 408, 155-61. DOI ScienceOn |
36 | Vasala K, Paakko P, Turpeenniemi-Hujanen T (2008). MMP-9 immunorecative protein in urinary bladder cancer: a marker of favorable prognosis. Anticancer Res, 28, 1757-67. |
37 | Yeh YC, Sheu BS, Cheng HC, et al (2010). Elevated serum MMP-3 and -7 in H. pylori-related gastric cancer can be markers biomarkers correlating with a poor survival. Dig Dis Sci, 55, 1649-57. DOI |
38 | Ylisirnio S, Hoyhtya M, Turpeenniemi-Hujanen T (2000). Serum MMP-2, and -9 and TIMP-1, -2 in lung cancer-TIMP-1 as prognostic marker. Anticancer Res, 20, 1311-6. |
39 | Yukawa N, Yoshikawa T, Akaike M, et al (2007). Impact of plasma tissue inhibitor of matrix metalloproteinase-1 on long-term survival in patients with colorectal cancer. Oncology, 72, 205-8. DOI ScienceOn |
40 | Zhou JH, Zhang B, Kernstine KH, Zhong L (2011). Autoantibodies against MMP-7 as a novel diagnostic biomarker in esophageal squamous cell carcinoma. World J Gastro, 17, 1373-8. DOI ScienceOn |